2 terminated, 1 completed, 1 recruiting. 3 Phase 1, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Terminated 2, Completed 1 |
| Early Phase 1 | 1 | Recruiting 1 |
Follow Incuron: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma CBL0137, Ipilimumab, Nivolumab - Locally Advanced or Metastatic Melanoma | Early Phase 1 | Recruiting | Fox Chase Cancer Center | 12 | 2022-11-30 | 2026-05-22 |
| CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma FACT Complex-targeting Curaxin CBL0137 - Advanced Cutaneous Melanoma of the Extremity, Advanced Sarcoma of the Extremity | Phase 1 | Terminated | Roswell Park Cancer Institute | 7 | 2019-07-01 | 2024-03-27 |
| Study of IV CBL0137 in Previously Treated Hematological Subjects CBL0137 - Hematological Malignancies | Phase 1 | Terminated | Incuron | 5 | 2017-01-01 | 2020-12-10 |
| A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm CBL0137 - Solid Tumors, Glioblastoma | Phase 1 | Completed | Incuron | 83 | 2013-07-01 | 2020-12-10 |
Glioblastoma (1) · Hematologic Neoplasms (1) · Hodgkin Disease (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myeloid, Acute (1) · Lymphoma, Follicular (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Mantle-Cell (1) · Melanoma (1) · Multiple Myeloma (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
CBLC137 (4) · Ipilimumab (1) · Nivolumab (1)
United States (4)
Afshin Dowlati, MD (1) · Anthony Olszanski, MD (1) · John Sarantopoulos, MD (1) · Joseph Skitzki (1) · Langdon Miller, MD (1) · Manmeet Ahluwalia, MD (1) · Renuka Iyer, MD (1)